Abstract. HDAC inhibitors (HDACis) represent a class of anticancer agents including suberoylanilide hydroxamic acid (SAHA, Vorinostat), which has shown a strong antitumor effect, both in vitro and in vivo. Induction of apoptotic genes is an important pathway of SAHA cytotoxic mechanism of action and it has been largely described that SAHA induces sensitization of cell death receptor-resistant breast cancer cells to apoptosis. In this study, we investigated the activation of some apoptotic genes which could be responsible for the in vivo antitumor potency of SAHA in a model of human breast cancer. We found that the apoptotic gene pattern induced by SAHA in the MDA-MB-231 cell line involves the upregulation of some molecules belonging to the TNF superfamily. In particular, we demonstrated that the upregulation of the CD137 receptor/ligand system correlates with a synergistic cytotoxic effect when MDA-MB-231 cells are treated with the combination of SAHA and soluble CD137 receptor. To our knowledge, this is the first study to indicate that this member of the TNF superfamily, CD137, is modulated by SAHA treatment in breast cancer cells, suggesting that the combination of SAHA with this TNF-related receptor could be a new therapeutic approach for the treatment of tumors.
Introduction
Altered acetylation and deacetylation of the histones is often associated with cancer since it causes changes in the expression pattern of genes involved in the regulation of cell proliferation and apoptosis (1, 2) . It is well known that hyperacetylation of histones H3 and H4 correlates with gene activation whereas deacetylation mediates chromatin condensation and gene transcription silencing (3) .
HDAC inhibitors (HDACis) are a new group of anticancer agents and are currently evaluated in several phase I and phase II clinical trials in patients with hematologic and solid malignancies (4, 5) . Five chemical classes of HDACis have been characterized including benzamides (MS-275), hydroxamic acids (SAHA and trichostatin A), short-chain fatty acids (sodium butyrate and phenylbutyrate), cyclic tetrapeptide containing a 2-amino-8-oxo-9,10-epoxy-decanoyl moiety (trapoxin A) and cyclic peptides without the 2-amino-8-oxo-9,10-epoxy-decanoyl moiety (FK228). Recent studies have shown that HDAC inhibitors induce cell cycle arrest, differentiation, and apoptosis in vitro and in vivo (6) . HDACis also inhibit endothelial cell proliferation and angiogenesis by down-regulating angiogenesis-related gene expression (7) . Two HDACis, SAHA and romidepsin (depsipeptide or FK228), have been approved by the US Food and Drug Administration for the treatment of cutaneous T cell lymphoma (8, 9) . Since breast cancer is the highest cause of tumor death in women, the antitumoral potency of HDACis on human breast tumor cells has been widely investigated.
In breast cancer cell lines, SAHA has been demonstrated to suppress the growth of tumor cells in vitro at low micromolar concentrations (10) . Growth inhibition was associated with cell cycle arrest, morphological and functional differentiation and apoptosis. In vivo, in tumor xenograft models, SAHA significantly inhibits tumor growth of human breast cancer cells without apparent toxicity in animals (11) .
Several studies have demonstrated that HDACis can sensitize cancer cells to apoptosis induced by Apo2L/TRAIL, Gleevec, chemotherapeutic agents and ionizing radiations (12, 13) , and also sensitization of breast cancer cells to topoisomerase II inhibitors by SAHA treatment has been reported, indicating that HDACis may be capable of enhancing the effectiveness of apoptosis-inducing agents used clinically (14) . Although many studies have demonstrated the effect of histone acetylation on the re-expression of ERα receptors (15) , the activation/repression by HDACis of apoptotic genes which could counteract the SAHA/Vorinostat induces the expression of the CD137 receptor/ ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line
aggressive behaviour of ER(-) breast cancer cells is still matter of investigation (16, 17) .
This study was designed to analyze genes involved in SAHA-induced cell death pathways. In fact we observed a different antitumoral potency of SAHA in vivo and in vitro cytotoxicity experiments on the human breast cancer cell line MDA-MB-231, which is ER(-) and expresses mutant p53, when compared to the ER(+)/wild-type p53 MCF7 cell line. Here, we found that SAHA has different effects on the two breast cancer cell lines, as regard to H4 histone acetylation, cell cycle, apoptosis kinetics, but above all on the expression of apoptotic genes. In particular TNF superfamily molecules (TRAIL, CD137, CD70/CD27) are strongly upregulated in MDA-MB-231 cells and we demonstrated that the combination of SAHA with the soluble CD137 receptor exerts a synergistic effect on MDA-MB-231 cell death. On the contrary, in MCF7 cells, apoptosis seems to be TNFR-independent and CD137 upregulation is absent. Thus, these results enlarge the field of application of the therapeutical approach which combines HDACis and TNF receptor family molecules, suggesting that the combination of HDACis plus soluble CD137 receptor could be useful in killing CD137L positive human breast cancer cells.
Materials and methods
Reagents and chemicals. Suberoylanilide hydroxamic acid (SAHA, Vorinostat), was synthesized in the Department of Chemistry of Menarini Ricerche SpA (Pomezia, Italy). DMSO was purchased from Sigma (St. Louis, MO, USA). Anti-CD137-APC and anti-CD137L-PE antibodies and APCand PE-stained isotype controls were purchased from BD Pharmingen (San Diego, CA, USA). FcR blocking reagent and 10% BSA solution were purchased from Miltenyi Biotech (Bergish Gladback, Germany).
Cell culture. The human mammary adenocarcinoma cell line ER(-), MDA-MB-231, was purchased from ATCC (American Type Culture Collection, VA, USA). The human mammary adenocarcinoma cell line ER(+), MCF7, was kindly provided by Dr F. Zunino (Istituto Nazionale Tumori, Milan, Italy). MDA-MB-231 cells were propagated in Leibovitz's L-15 medium supplemented with 10% foetal bovine serum (FBS) and 2 mM L-glutamine (Gibco). MCF7 cells were propagated in Eagle's minimum essential medium supplemented with 0.01 mg/ml bovine insulin, 10% FBS and 2 mM L-glutamine. Cells were cultured at 37˚C in a 5% CO 2 /95% air humidified atmosphere.
Cell treatments. In apoptosis experiments, sub-confluent cells were cultured for 24-or 48-h in the presence of equitoxic concentrations of SAHA, corresponding to the IC 90 previously determined for each cell line (50 and 10 µM for MDA-MB-231 and MCF7 cells, respectively). Experiments to detect acetylated lysine were performed in the presence of SAHA IC 50 (5 and 1 µM for MDA-MB-231 and MCF7 cells, respectively), incubating cells for 24 h in the continous presence of the drug.
In vitro cytotoxicity assay. Drug-induced cytotoxic effects were evaluated by using Alamar Blue assay (18 . SAHA was dissolved in DMSO and stored at -80˚C. This stock solution was diluted just before dosing with D5W (dextrose 5%) to a final DMSO concentration not superior to 1%. SAHA was admini stered i.v. at a dose of 50 mg/kg in a volume corresponding to 10 ml/kg body weight. Tumor-bearing mice were treated with SAHA or vehicle once daily, 5 days/week, for a total of 10 doses, starting when tumors were approximately 50 mm 3 in volume. No adverse or toxic effect were observed at this dose level. All animal experiments were reviewed and approved by the Ethics commission at Menarini Ricerche according to the guidelines of the European Directive for the protection of vertebrate animals used for experimental and other scientific purposes (2010/63/UE). 
Quantitative analysis of acetylated lysine by flow cytometry.
After treatment with the HDACi, cells were trypsinized and fixed in 4% paraformaldehyde for 10 min at room temperature. Paraformaldehyde was used for fixation of cells since it has been found to preserve the structure of acetylated chromatin organization. After fixation, cells were washed three times and permeabilized with PBS containing 0.4% Triton X-100 and 0.1% BSA. 5x10 5 cells/tube resuspended in PBS + 0.5% BSA were labelled with a polyclonal rabbit antibody which recognizes hyperacetylated histone H4 (Upstate Biotechnology) at a dilution of 1:50 for 1 h at 4˚C. Subsequently, cells were washed twice, incubated with a FITC-conjugated polyclonal anti-rabbit antibody (Santa Cruz Biotechnology) for at least 30 min at 4˚C and then resuspended in 1 ml PBS + 0.5% BSA. As background controls we used both a specific rabbit IgG and a sample stained only with the secondary antibody. Fluorescence of acetylated lysine was determined on a FacsCanto flow cytometer (BD Biosciences) and expressed in logarithmic arbitrary units as mean fluorescence intensity (MFI). Data analysis was performed using FacsDiva 6.1.2 version software. Background and unstained controls were used to correctly set analysis gates so that CD137-and CD137L-positive quadrants in isotype samples do not contain more than 2% of cells. Data analysis was performed using FacsDiva 6.1.2 version software.
HDAC activity in cellular extracts. HDAC activity in nuclear extracts was measured according to the manufacturer's instructions (HDAC Fluorescent assay, Biomol International LP, PA). Nuclear extracts were prepared using the kit NE-PER (Pierce Biotechnology) and incubated (5 µg/well) at 25˚C with 40 µM of Fluor de Lys™ substrate. Reactions were stopped after 30 min with Fluor de Lys™ developer and fluorescence measured using a Victor1420 microplate reader (Wallac, Finland) at ex/em 355/460 nm. Results are the mean of three independent experiments ± SD.
RNA extraction and cDNA synthesis. Total RNA was extracted from cells using the SV Total RNA Isolation System (Cat no. Z3100, Promega, WI, USA). Briefly, cells from 1.5x10 6 to a maximum of 2.5x10 6 per treatment were lysed in 175 µl lysis buffer. Lysates were subjected to purification with silica columns according to the instructions of the manufacturer. The yield of total RNA was determined spectrophotometrically at 260 nm, while its integrity was determined by denaturing agarose gel electrophoresis. For each sample, 5 µg total RNA were copied into cDNA with the RT2 First Strand Kit (Cat no. C-03, SuperArray, MD, USA). Finished reactions had a volume of 20 µl and were stored at -20˚C until they were used in realtime PCR analysis.
Gene array analysis by real-time PCR. The cDNA samples were pre-diluted to 100 µl and mixed with RT2 qPCR Master Mix (Cat no. PA-012, SuperArray) to a final volume of 2550 µl. The master mix contains all the reagents and buffers required for the real-time PCR in our 7300 real-time PCR system (Applied Biosystems, CA, USA), including the SYBR Green dye and the ROX reference dye. The gene expression analysis was performed by adding 25 µl of the experimental cocktail to each well of a 96-well RT2 Profiler PCR Array for human apoptosis (Cat no. PHAS-012A, SuperArray). In this array, each well contains a primer pair specific for one of 84 key genes involved in human apoptosis, besides housekeeping genes and control wells (Fig. 1) . After an initial denaturation at 95˚C for 10 min, the cycling program was 95˚C, 15 sec and 60˚C, 1 min for 40 cycles. Raw data were analyzed with the ΔΔCt method using an Excel-based PCR Array Data Analysis Template (SuperArray). Data from control cells were set as calibrator for the relative quantification.
CD137 ligand mRNA by real-time PCR.
To determine the mRNA expression levels of target genes, duplicates of the cDNA samples, corresponding to 150 ng of total RNA, were amplified in the presence of 12.5 µl of 2X TaqMan Universal PCR Master Mix and 1.25 µl of 20X inventoried TaqMan Gene Expression Assay (Applied Biosystems) to a final volume of 25 µl. The TaqMan Gene Expression Assays were: Hs00155512_m1 for TNFRSF9 (CD137), Hs00169409_m1 for TNFSF9 (CD137L) and Hs99999905_m1 for GAPDH. The samples of cDNA were also amplified in the presence of Hs99999903_m1 for human β-actin to normalize mRNA quantities. After 10 min of incubation at 95˚C for denaturation, samples were subjected to 45 cycles of PCR. Each cycle was 95˚C for 15 sec and 60˚C for 1 min. The amplification took place in a 7300 real-time PCR system (Applied Biosystems). The collected data of gene expression were the number of cycles needed to reach a fixed threshold fluorescence (Ct 
Results

SAHA-induced cell death in in vitro and in vivo models.
In our in vitro Alamar Blue assay, SAHA showed a cytotoxic activity with an IC 50 of 5 and 1 µM in MDA-MB-231 and MCF7 cells, respectively (Fig. 1A) . When xenografted nude mice were treated with SAHA 50 mg/kg per os, both tumor models, characterised by a different estrogen receptor and p53 status, appeared sensitive to the inhibitory effect of SAHA (Fig. 1B  and C) . A more pronounced and long-lasting inhibition of tumor growth of MDA-MB-231 cells with respect to MCF7 tumor cell line was observed.
Since in several studies it has been described that SAHA exerts its antitumor effect through apoptosis induction, we investigated the presence of apoptotic cell death using the IC 90 concentration of this HDACi. Table I shows that, in MCF7 cells, 10 µM SAHA causes a slower increase of apoptosis, which at 24 h measures 17%, compared to the 43% of 50 µM SAHAtreated MDA-MB-231 cells. At 48 h MCF7 cells showed a drastic increase of apoptosis (45%), while the ERα negative cells remained quite stable (40%). Thus, the kinetics of SAHAinduced apoptosis in these cell lines seems to be quite different, probably because of the distinct pathways involved (see below). Table I . Apoptosis detection by flow cytometry using Annexin/ 7-ADD method (Materials and methods). These results are in agreement with the cytotoxicity assay, confirming a lower in vitro sensitivity of MDA-MB-231 cells also to SAHA-induced apoptotic cell death.
a % Apoptosis -----------------------------------------------------------------------------
H4 histone acetylation and inhibition of HDAC activity. As shown in Fig. 2 , when HDAC activity was measured in nuclear extracts, we found that SAHA exerted an inhibitory effect that was quite similar between MDA-MB-231 and MCF7 cells. The flow cytometric analysis of H4 histone acetylation revealed that, in untreated MDA-MB-231 cells, the basal level of acetylation was higher than that measured in MCF7 cells. When cells were incubated for 24 h with equitoxic concentration of SAHA (IC 50 ), an increase of histone acetylation was observed, and again it was more pronounced in MDA-MB-231 than in MCF7 cells (percentage increase of 75% and 21%, respectively) (Table II) . Since histone acetylation favours chromatin relaxation and gene expression, this observation seems to correlate well with the earlier induction of apoptosis seen at 24 h in MDA-MB-231 cells.
Effect of SAHA on apoptotic gene expression. When we investigated the pattern of apoptotic genes induced or repressed by SAHA (Fig. 3A) , we found that, in the two human breast tumor cell lines, mRNAs related to different apoptotic pathways were expressed. Variations with more than 3-fold increase/decrease have been considered significant. In MDA-MB-231 cells an upregulation of genes which are associated to the extrinsic apoptotic death receptor pathway was observed, such as TNFSF10 (TRAIL), TNFSF8 (CD30L), CD27, CD70, TNFRSF25 (DR3), caspase 8. In particular a strong upregulation (more than 10-fold) of TNFRSF9 (CD137 receptor) and of CD137 ligand transcription has been measured ( Fig. 3 ) and protein expression confirmed by flow cytometry (Fig. 4) . Factors involved into the mitochondrial pathway were not particularly affected in this cell line. On the contrary, in MCF7 cells, the intrinsic apoptotic pathway seems to be involved: in fact the TNF-superfamily genes were not induced by SAHA treatment, but genes encoding for proapoptotic factors such as p53 binding protein 2 (TP53BP2) and BNIP3 were upregulated. Furthermore, in MDA-MB-231 cells, caspases 4, 5 and 7 rather then caspase 3 seem to be activated while in MCF7 cells, which are caspase 3-deprived, we observed a strong increase of caspase 14 mRNA, suggesting that in this cell line this caspase could become the final effector of the apoptotic signalling.
Effect of the combination of SAHA and soluble CD137 on cytotoxicity/apoptosis in MDA-MB-231 cells. To assess the existence of a functional significance of CD137 receptor/ligand upregulation, we combined treatment of SAHA with soluble CD137 receptor and related molecules. Fig. 5A shows that the simultaneous administration of 5 µM SAHA with the soluble form of CD137 receptor induced the most significant enhancement of cell death, when compared to single-drug conditions or to the combination with other agonists (Fig. 5B-D) . When 1 µM SAHA was assayed in the Apotox assay in order to reduce the cytotoxicity of single-drug treatment, a more pronounced effect was observed, with a synergism of action (CI 0.24) at the 72-h time point (Fig. 6) .
Discussion
In the present study we showed for the first time that an HDACi promotes CD137/CD137L upregulation in a solid tumor in particular in a breast cancer cell line. Moreover, we found that the simultaneous administration of SAHA and soluble CD137 receptor exerts a synergistic effect on cancer cell destruction. Many investigators have demonstrated that HDACis exert their anticancer activity by inducing apoptosis and modulating the in vivo environment of tumor cells (7, 23, 24) . Furthermore, it has been also described that HDACis sensitize breast cancer cells to TRAIL induced apoptosis (25, 26) , while a recent paper of Vire et al reported CD137/CD137L induction by HDACis in haematological cancer cells (27) , however, many aspects of their in vivo cytotoxic action remain to be elucidated. Our findings demonstrated that, in MCF7 cells, SAHA activates the intrinsic apoptotic pathway through induction of genes related to p53 signalling, while, in MDA-MB-231 cells, SAHA treatment increases the transcription of genes involved in the cell death pathway, such as TNFSF10 (TRAIL), caspase 8, and even more the genes encoding for the CD137 and CD70 receptor/ligand system. The CD137 receptor (TNFRSF9, 4-1BB, ILA) is a member of the tumor necrosis factor receptor family, and a potent T cell co-stimulatory molecule. Its natural ligand, CD137 ligand (TNFSF9, CD137L-4-1BBL), has been detected on professional APCs including B cells, macrophages, dendritic cells and can transduce signals, a process known as 'reverse signalling' (28, 29) . The bidirectional signalling of CD137L usually induces activation, proliferation and migration of monocytes and hematopoietic progenitor cells. However, a recent study reported that CD137L engagement can also inhibit cell proliferation and induce apoptosis in multiple myeloma cell lines (30) .
Other receptors, such as CD40, have shown a similar double behaviour, suggesting that the final effect of these receptor/ ligand systems is probably dependent on tumor cell type and on the induction of other bifunctional molecules (31) . Our data showed also that the stimulation of CD137 receptor was not particularly effective in increasing cell death, despite its higher expression on MDA-MB-231 cells, and no synergism or additive effect was measured following combination of SAHA with CD137L or with an anti-CD137 antibody. Thus these results seem to confirm the observations of Gullo et al on the prevalent role of CD137L in activating a cell death signal in human tumor cells (30) . Furthermore, the presence of a mutated p53 in this cell line, could account for the activation of the extrinsic apoptotic pathway and for its in vitro reduced sensitivity to SAHA. Recent studies reported that re-expression of CD70 in tumor cells may induce an anti-tumor response by T-lymphocytes and that the epigenetic downregulation of CD70 receptor by DNA hypermethylation is a strategy of breast cancer cells to escape immune response (32) . Our observation that SAHA-induced histone hyperacetylation determines also an overexpression of CD70 and CD27 in MDA-MB-231 cells, supports the idea that SAHA treatment could restore an immune response against cancer cells. So our initial results showing that MDA-MB-231 cells are more sensitive to SAHA treatment in the in vivo tumor xenograft model than in in vitro assays, when compared to the MCF7 cell line, could be explained by the concurrent overexpression of multiple death receptors/ligands. Since in solid tumors the presence of soluble forms of CD137, TRAIL and of autocrine and paracrine factors which affect cancer development has been documented (33, 34) , it is possible that the stimulation of overexpressed receptors/ligands contributes to the enhancement of apoptosis and to the regression of tumor mass.
In conclusion, our study demonstrated that SAHA can activate different apoptotic genes and targets depending on the type of breast cancer cell line studied, and that promotes, in a p53-mutated breast cancer cell line, the expression of cell death molecules such as CD137/CD137L. These findings suggest that the induction of death receptors could contribute to enhancing in vivo SAHA activity on breast tumors and that the combi nation of SAHA with soluble CD137 receptor could be a new further approach in breast cancer therapy.
